202 related articles for article (PubMed ID: 23046037)
1. Landmarks in hormonal therapy for prostate cancer.
Hammerer P; Madersbacher S
BJU Int; 2012 Oct; 110 Suppl 1():23-9. PubMed ID: 23046037
[TBL] [Abstract][Full Text] [Related]
2. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
[TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
4. [Management of enzalutamide, a new hormonal therapy].
Beuzeboc P; Benderra MA; de La Motte Rouge T
Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.
Payne H; Mason M
Br J Cancer; 2011 Nov; 105(11):1628-34. PubMed ID: 22009028
[TBL] [Abstract][Full Text] [Related]
6. [Pathophysiology and therapy of castration-resistant prostate cancer].
Merseburger AS; Kuczyk MA; Wolff JM
Urologe A; 2013 Feb; 52(2):219-25. PubMed ID: 23160609
[TBL] [Abstract][Full Text] [Related]
7. PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients.
Fersino S; Borghesi S; Jereczek-Fossa BA; Arcangeli S; Mortellaro G; Magrini SM; Alongi F;
Radiol Med; 2021 Mar; 126(3):460-465. PubMed ID: 32852750
[TBL] [Abstract][Full Text] [Related]
8. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
Merseburger AS; Hupe MC
Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
[TBL] [Abstract][Full Text] [Related]
9. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
[TBL] [Abstract][Full Text] [Related]
11. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
[TBL] [Abstract][Full Text] [Related]
12. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
Clinton TN; Woldu SL; Raj GV
Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
[TBL] [Abstract][Full Text] [Related]
13. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
[TBL] [Abstract][Full Text] [Related]
14. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
Marks LS
Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507
[TBL] [Abstract][Full Text] [Related]
16. Targeting the androgen receptor.
Friedlander TW; Ryan CJ
Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
[TBL] [Abstract][Full Text] [Related]
17. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
18. [Hormonal treatment in prostate cancer].
Bastide C; Bruyère F; Karsenty G; Guy L; Rozet F
Prog Urol; 2013 Nov; 23(15):1246-57. PubMed ID: 24183083
[TBL] [Abstract][Full Text] [Related]
19. Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis.
Ghashghaei M; Kucharczyk M; Elakshar S; Muanza T; Niazi T
Curr Oncol; 2019 Oct; 26(5):e640-e650. PubMed ID: 31708657
[TBL] [Abstract][Full Text] [Related]
20. The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.
Lieberman R
Am J Ther; 2013; 20(2):128-31. PubMed ID: 23466618
[No Abstract] [Full Text] [Related]
[Next] [New Search]
